Abstract
Advanced or recurrent endometrial cancer is relatively uncommon and carries a poor prognosis. Recent decades have failed to witness a significant improvement in treatment outcomes for women with advanced disease, and mortality rates remain high. The precise role of surgical debulking, radiotherapy, hormonal therapy and cytotoxic chemotherapy in the treatment of advanced or recurrent disease is unclear. An improved understanding of the molecular pathology of endometrial cancer has allowed biologically relevant targets to be characterized and novel drugs are now being tested in early-Phase clinical trials. This review will present the evidence for the therapeutic options currently available to women with advanced or recurrent endometrial cancer and describe the progress that is being made in the field. © 2009 Expert Reviews Ltd.
| Original language | English |
|---|---|
| Pages (from-to) | 521-532 |
| Number of pages | 11 |
| Journal | Expert Review of Obstetrics and Gynecology |
| Volume | 4 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sept 2009 |
Keywords
- advanced endometrial cancer
- chemotherapy
- hormonal therapy
- radiotherapy
- recurrent endometrial cancer
- surgery
- targeted therapy
